CA2453572A1 - The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction - Google Patents

The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction Download PDF

Info

Publication number
CA2453572A1
CA2453572A1 CA002453572A CA2453572A CA2453572A1 CA 2453572 A1 CA2453572 A1 CA 2453572A1 CA 002453572 A CA002453572 A CA 002453572A CA 2453572 A CA2453572 A CA 2453572A CA 2453572 A1 CA2453572 A1 CA 2453572A1
Authority
CA
Canada
Prior art keywords
compounds
enhance
effects
apomorphine
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002453572A
Other languages
English (en)
French (fr)
Inventor
Jose Esteve-Soler
Inigo Saenz De Tejada-Gorman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2453572A1 publication Critical patent/CA2453572A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002453572A 2001-07-02 2002-07-01 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction Abandoned CA2453572A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP0101535 2001-07-02
ES200101535A ES2180446B1 (es) 2001-07-02 2001-07-02 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
PCT/ES2002/000325 WO2003004097A1 (es) 2001-07-02 2002-07-01 Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil

Publications (1)

Publication Number Publication Date
CA2453572A1 true CA2453572A1 (en) 2003-01-16

Family

ID=8498259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002453572A Abandoned CA2453572A1 (en) 2001-07-02 2002-07-01 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction

Country Status (14)

Country Link
US (2) US20040143010A1 (enExample)
EP (1) EP1413332B1 (enExample)
JP (1) JP2005501031A (enExample)
AR (1) AR036124A1 (enExample)
AT (1) ATE419012T1 (enExample)
BR (1) BR0211315A (enExample)
CA (1) CA2453572A1 (enExample)
DE (1) DE60230629D1 (enExample)
ES (2) ES2180446B1 (enExample)
HU (1) HUP0400924A3 (enExample)
MX (1) MXPA04000007A (enExample)
NO (1) NO20040007L (enExample)
PL (1) PL367766A1 (enExample)
WO (1) WO2003004097A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
RU2281101C2 (ru) * 2004-10-01 2006-08-10 Юрий Михайлович Есилевский Способ лечения больных хроническим простатитом
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
CN109678764A (zh) * 2018-12-05 2019-04-26 湖北广辰药业有限公司 一种羟苯双磺酸及其钙盐和制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681503A (en) * 1970-04-17 1972-08-01 Om Lab Sa Method for combating disturbances of the lipid content of the blood
US4252821A (en) * 1979-12-07 1981-02-24 Laboratoires Om Societe Anonyme Method for treating ulcers
US4511557A (en) * 1981-08-24 1985-04-16 Gauri Kailash Kumar Pharmaceutical composition
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
RU1776408C (ru) * 1990-08-13 1992-11-23 Одесский Медицинский Институт Им.Н.И.Пирогова Способ лечени гломерулонефрита
EP0954298B1 (fr) * 1996-04-03 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Derives 2,5-dihydroxybenzenesulfoniques pour le traitement de la dysfonction sexuelle
HU225149B1 (en) * 1996-12-30 2006-07-28 Teva Gyogyszergyar Zrt Use of dobesilate salts for the manufacture of medicaments for the treatment or prevention of embryonic retardation or discordance
US6403643B1 (en) * 1997-04-03 2002-06-11 Laboratories Del Dr. Esteve, S.A. Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition

Also Published As

Publication number Publication date
EP1413332A1 (en) 2004-04-28
MXPA04000007A (es) 2004-05-21
DE60230629D1 (de) 2009-02-12
JP2005501031A (ja) 2005-01-13
HUP0400924A2 (hu) 2004-07-28
ES2180446A1 (es) 2003-02-01
HUP0400924A3 (en) 2007-11-28
US20040143010A1 (en) 2004-07-22
ATE419012T1 (de) 2009-01-15
BR0211315A (pt) 2004-09-28
EP1413332B1 (en) 2008-12-31
AR036124A1 (es) 2004-08-11
PL367766A1 (en) 2005-03-07
WO2003004097A1 (es) 2003-01-16
US20070197543A1 (en) 2007-08-23
NO20040007L (no) 2004-02-23
ES2180446B1 (es) 2004-01-16
ES2318023T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
EP1413332B1 (en) Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
AR036448A1 (es) Composiciones farmaceuticas de conjugados droga insulina-oligomeros, y metodos para tratar las enfermedades con los mismos
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
JP6163633B2 (ja) 疼痛、そう痒および炎症を処置するために局所的に投与されるストロンチウム含有複合体
WO2003001982A3 (en) Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
EA200400888A1 (ru) Фармацевтически приемлемые тельца, несущие фосфат глицерина
ES2330795T3 (es) Combinaciones de agentes vasoactivos y su uso en el tratamiento de disfunciones sexuales.
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
WO2004058268A3 (de) Verwendung von tetrahydrobiopterinderivaten zur behandlung und ernährung von patienten mit aminosäurestoffwechselstörungen
DE60022478D1 (de) Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen
CA3168207A1 (en) Cellular uptake
WO2004043365A3 (en) Method for treatment of premature ejaculation in humans
Mozhayeva et al. The effect of frusemide on oxytocin‐induced contractions of the rat myometrium
RU2568588C2 (ru) Применение воды с отрицательным окислительно-восстановительным потенциалом меньше нуля в качестве основы гелей для билогически активных добавок в виде геля.
SU886907A1 (ru) Способ лечени ожогов
RU2004105765A (ru) Способ лечения дистрофических заболеваний заднего полюса глаза
Marin et al. Peloidotherapy in osteoarthritis-modulation of oxidative stress
KR102151155B1 (ko) 난청의 예방 또는 치료용 조성물
RU2177307C1 (ru) Лечебно-косметическое средство
BR102022009993A2 (pt) Composto polivalente de cura da covid-19 e de doenças causadas por quaisqueres microorganismos e prevenção de cânceres causados por radicais-livres (tanicina)
Cattell Lippincott's New Medical Dictionary: A Vocabulary of the Terms Used in Medicine, and the Allied Sciences, with Their Pronunciation, Etymology, and Signification, Including Much Collateral Information of a Descriptive and Encyclopedic Character
RU2003117781A (ru) Способ лечения туберкулеза
Udovicic DIPLOMARBEIT/DIPLOMA THESIS

Legal Events

Date Code Title Description
FZDE Discontinued